
IMGN
Healthcare · Biotechnology · $8.72B market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2023
EPS trend, 90 days to now · +8.3% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 2, 2023 | Before the open | 0.04 | 0.10 | +150.0% |
| Jul 31, 2023 | Before the open | -0.14 | -0.02 | +85.7% |
| Apr 28, 2023 | Before the open | -0.25 | -0.16 | +36.0% |
| Mar 1, 2023 | Before the open | -0.30 | -0.23 | +23.3% |
| Nov 4, 2022 | Before the open | -0.25 | -0.31 | -24.0% |
| Jul 29, 2022 | Before the open | -0.21 | -0.24 | -14.3% |
| May 6, 2022 | Before the open | -0.21 | -0.10 | +52.4% |
| Feb 25, 2022 | Before the open | -1.71 | -0.17 | +90.1% |
| Oct 29, 2021 | Before the open | -0.18 | -0.18 | 0.0% |
| Jul 30, 2021 | Before the open | -0.18 | -0.15 | +16.7% |
| May 10, 2021 | Before the open | -0.19 | -0.17 | +10.5% |
| Feb 12, 2021 | Before the open | -0.08 | 0.16 | +300.0% |
| Nov 6, 2020 | Before the open | -0.18 | -0.13 |
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian,…
| +27.8% |
| Jul 31, 2020 | Before the open | -0.17 | -0.14 | +17.6% |
| May 1, 2020 | Before the open | -0.15 | -0.17 | -13.3% |
| Feb 14, 2020 | Before the open | -0.05 | 0.03 | +160.0% |
| Nov 1, 2019 | Before the open | -0.18 | -0.15 | +16.7% |
| Aug 2, 2019 | Before the open | -0.33 | -0.29 | +12.1% |
| May 3, 2019 | Before the open | -0.20 | -0.30 | -50.0% |
| Feb 8, 2019 | Before the open | -0.32 | -0.28 | +12.5% |
| Nov 2, 2018 | Before the open | -0.32 | -0.32 | 0.0% |
| Jul 27, 2018 | Before the open | -0.29 | -0.31 | -6.9% |
| May 4, 2018 | Before the open | -0.25 | -0.30 | -20.0% |
| Feb 9, 2018 | Before the open | -0.12 | -0.11 | +8.3% |